Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 8:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Metastatic Pancreatic Cancer, Pancreatic Cancer
Interventions: IMMU-107, placebo, Gemcitabine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 42
States / cities: Gilbert, Arizona • Duarte, California • Long Beach, California + 33 more

Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions: Exenatide, Normal Saline; Drug · Other
Lead sponsor: Carl T. Hayden VA Medical Center; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8
Interventions: Avelumab, Peripheral Blood Collection, Placebo; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 9
States / cities: Orange, California • Aurora, Colorado • Tampa, Florida + 6 more

Conditions: Sleep Restriction
Interventions: Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 60 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Torrance, California

Conditions: Sickle Cell Anemia
Interventions: Regadenoson, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 10 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Oakland, California • Chicago, Illinois • Baltimore, Maryland + 7 more

Conditions: Major Depressive Disorder
Interventions: Lipopolysaccharide, Placebo; Biological
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Anesthesia, Local
Interventions: AG-920, Placebo; Drug
Lead sponsor: American Genomics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Schizophrenia
Interventions: MK-5720, Placebo to MK-5720, MK-8189, Placebo to MK-8189; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Glendale, California • Hallandale, Florida • Hollywood, Florida + 1 more

Conditions: Otolaryngeal Cancer
Interventions: Ketamine, Placebo, Electroencephalogram (EEG); Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Post Operative Blood Loss
Interventions: Tranexamic Acid, Normal Saline Solution; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: COVID-19, SARS-CoV-2
Interventions: VYD222 (pemivibart), Normal saline; Drug
Lead sponsor: Invivyd, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 790 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 18
States / cities: Fullerton, California • Long Beach, California • Rolling Hills Estates, California + 15 more

Conditions: Acute Bronchiolitis
Interventions: 3% Hypertonic Saline, 0.9 % normal saline; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 2 Months to 12 Months
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Ovarian Cancer
Interventions: MORAb-003 (farletuzumab), 0.9% Saline, Paclitaxel; Drug
Lead sponsor: Morphotek; Industry
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 34
States / cities: Mobile, Alabama • Phoenix, Arizona • Greenbrae, California + 29 more

Conditions: Acute Kidney Injury
Interventions: Amino Acids, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 1 Day to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: IgG4 Related Disease, IgG4-RD
Interventions: elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota

Conditions: Acute Kidney Injury
Interventions: Deferoxamine, Normal saline; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Trauma, Hemorrhagic Shock
Interventions: Type AB plasma, Crystalloid fluid (standard of care for resuscitation); Biological · Drug
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Application Site Discomfort, Medical Device Discomfort
Interventions: Bupivacaine with Epinephrine, Normal Saline; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Subarachnoid Hemorrhage, Stroke
Interventions: IV acetaminophen, Oral acetaminophen, Oral placebo, IV placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Pain
Interventions: Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min, Placebo Comparator: .9 normal saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer's Disease
Interventions: Placebo, octagam 10%; Drug · Biological
Lead sponsor: Octapharma; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hoboken, New Jersey

Conditions: COVID-19
Interventions: Crizanlizumab, 0.9% saline; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Congestive Heart Failure, Renal Insufficiency
Interventions: Hypertonic saline, then oral sodium chloride, Normal saline, then oral placebo capsule; Drug
Lead sponsor: Barnes-Jewish Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cytomegalovirus Infections
Interventions: Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine, Pentamer (high)/gB(med)/Adjuvant vaccine, Placebo (saline solution); Biological · Combination Product
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 18
States / cities: Anaheim, California • Long Beach, California • Los Angeles, California + 15 more

Search by objective public record fields.

Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

Adjuvant Avelumab in Merkel Cell Cancer

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

A Phase II Trial of Regadenoson in Sickle Cell Anemia

Lipopolysaccharide (LPS) Challenge in Depression

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients

Role of Topical Tranexamic Acid in Total Hip Arthroplasty

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis

An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

Amino Acids for Cardiac Surgery Associated AKI

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury

Control of Major Bleeding After Trauma Study

Control of Tourniquet Pain With an Axillary Ring of Subcutaneous Local Anesthetic

Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH

The Effect of Intraoperative Esmolol to Improve Postoperative Quality of Recovery and Pain After Ambulatory Surgery

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

Crizanlizumab for Treating COVID-19 Vasculopathy

Concentrated Saline Infusions and Increased Dietary Sodium With Diuretics for Heart Failure With Kidney Dysfunction

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults